Maravai LifeSciences Holdings, Inc.
MRVI
$4.15
-$0.14-3.26%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -15.35% | -28.34% | -30.47% | -19.95% | -11.76% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -15.35% | -28.34% | -30.47% | -19.95% | -11.76% |
| Cost of Revenue | -5.67% | -0.55% | 2.07% | 2.69% | -1.13% |
| Gross Profit | -31.63% | -67.05% | -68.32% | -46.69% | -25.28% |
| SG&A Expenses | -16.83% | -11.04% | -0.08% | 2.45% | 7.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.56% | -6.18% | 0.58% | 2.46% | 3.15% |
| Operating Income | 1.29% | -72.85% | -186.56% | -131.50% | -90.18% |
| Income Before Tax | 35.29% | 10.14% | -149.47% | -158.25% | -148.64% |
| Income Tax Expenses | -129.81% | -126.45% | -100.55% | -100.50% | -100.26% |
| Earnings from Continuing Operations | 36.41% | 11.12% | 33.91% | -105.32% | -81.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -37.26% | -12.88% | -5.90% | 366.19% | 343.30% |
| Net Income | 35.74% | 9.72% | 46.20% | -43.36% | -24.17% |
| EBIT | 1.29% | -72.85% | -186.56% | -131.50% | -90.18% |
| EBITDA | 4.67% | -205.02% | -13,419.57% | -3,135.03% | -920.10% |
| EPS Basic | 37.13% | 12.21% | 48.97% | -33.27% | -15.89% |
| Normalized Basic EPS | -79.83% | -83.72% | -100.56% | -85.03% | -86.96% |
| EPS Diluted | 37.13% | 12.21% | 48.97% | -33.14% | -15.77% |
| Normalized Diluted EPS | -79.83% | -83.72% | -100.56% | -85.03% | -86.96% |
| Average Basic Shares Outstanding | 3.16% | 4.69% | 5.96% | 7.29% | 6.51% |
| Average Diluted Shares Outstanding | 3.16% | 4.69% | 5.96% | 7.29% | 6.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |